Sharon Dowell
Rheumatology · Washington, DCNPI 1225214463
Payments from drug & device makers
Across 368 payments — averaging $698.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$136K
- UCB SA$30K
- Amgen$23K
- Pfizer$18K
- AbbVie$17K
- Johnson & Johnson$15K
- plus $19K from 33 others
What the payments were for
- Consulting fees$30,46742%
- Speaking & faculty fees$28,80039%
- Travel & lodging$4,4276%
- Food & beverage$9,33213%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $136,391 |
| UCB SA | 10 | $29,746 |
| Amgen(2 entities) | 85 | $22,608 |
| Pfizer | 25 | $18,129 |
| AbbVie | 51 | $16,523 |
| Johnson & Johnson | 31 | $14,563 |
| UCB, Inc. | 16 | $10,320 |
| Cardinal Health 108 LLC | 7 | $2,421 |
| Janssen Research & Development, LLC | 2 | $1,702 |
| Mallinckrodt Enterprises LLC | 6 | $857 |
| GSK | 23 | $710 |
| Aurinia Pharma U.S., Inc. | 9 | $678 |
| AstraZeneca(2 entities) | 15 | $337 |
| Novartis | 12 | $261 |
| Genentech USA, Inc. | 6 | $225 |
| Regeneron Healthcare Solutions, Inc. | 4 | $208 |
| Sobi, Inc | 3 | $206 |
| Mallinckrodt Hospital Products Inc. | 8 | $193 |
| Merck | 12 | $189 |
| CSL Behring | 5 | $120 |
| Exelixis Inc. | 5 | $84 |
| Lilly USA, LLC | 3 | $77 |
| Boehringer Ingelheim | 3 | $52 |
| Sanofi | 1 | $48 |
| Incyte Corporation | 2 | $42 |
| AVEO Pharmaceuticals, Inc. | 2 | $41 |
| Phadia US Inc. | 2 | $39 |
| Eisai Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Emmaus Medical, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Circassia Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$257,035 in reported general payments places this provider in the 85th percentile of 41 rheumatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 24 | $197,737 |
| Humira(Cf) PenAdalimumab | 14 | $95,334 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $94,772 |
| OtezlaApremilast | 11 | $54,004 |
| ForteoTeriparatide | 13 | $53,434 |
| Hydroxychloroquine Sulfate | 101 | $3,219 |
| MethotrexateMethotrexate Sodium | 91 | $1,535 |
| Colchicine | 52 | $1,446 |
| Leflunomide | 30 | $1,367 |
| Pilocarpine Hcl | 19 | $904 |
| Febuxostat | 15 | $699 |
| Celecoxib | 14 | $445 |
| Prednisone | 61 | $412 |
| Alendronate Sodium | 48 | $268 |
| Meloxicam | 40 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $22,608 | $54,00411 claims |
| Lilly USA, LLCForteo | $77 | $53,43413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 rheumatology providers in District of Columbia.
Other rheumatology in Washington
- Stephen MitchellWashington$1.6M
- Virginia SteenWashington$785K
- Andrea Leonard-SegalWashington$633K
- Gail KerrWashington$573K
- Rodolfo CurielWashington$378K
- Mercedes QuinonesWashington$100K
- Christopher CollinsWashington$69K
- Saira BilalWashington$62K
- Megan LockwoodWashington$23K
- Victoria ShanmugamWashington$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.